What occurs in the other 20% of cancer patients with chemotherapy-induced nausea and vomiting (CINV)? A single-institution qualitative study

Daniel S. Childs, Sherry Looker, Jennifer Le-Rademacher, Jennifer L. Ridgeway, Carmen Radecki Breitkopf, Aminah Jatoi

Research output: Contribution to journalArticle

1 Citation (Scopus)

Abstract

Purpose: Despite recent advances in prophylaxis and management, 20% of patients who receive moderately to severely emetogenic chemotherapy continue to experience nausea and vomiting. Relying on patients’ own words, this study sought to capture and characterize the lived experience with chemotherapy-induced nausea and vomiting (CINV) for this important subgroup of patients. Methods: Solid tumor patients with a history of poorly controlled CINV provided informed consent and participated in a semi-structured interview, which was audio-recorded and transcribed. After data saturation, enrollment ceased, and inductive, qualitative analytic methods were employed. Results: The median age of the 20 enrolled patients was 56 years (range 27–83) with an equal gender split; half had gastrointestinal cancers. Two themes emerged. First, CINV is severe and multidimensional: “It’s like shredding your muscles… It’s doing it over and over again.” This symptom complex has psychosocial implications: “Isolation is a big thing.” Financial toxicity is also implicated: “I use [an antiemetic] when I feel like it is absolutely necessary because it is so expensive I cannot afford it anyway.” The second theme is underreporting of symptoms. Patients seemed to accept N/V as part of treatment and were therefore less forthcoming: “God, if you’re pumping poison in your system, you gotta expect some side effects.” Conclusions: These vivid data should motivate investigators to continue conducting clinical trials CINV and should remind healthcare providers about the importance of patient education on the availability of therapy for breakthrough symptomatology.

Original languageEnglish (US)
Pages (from-to)1-7
Number of pages7
JournalSupportive Care in Cancer
DOIs
StateAccepted/In press - Jun 25 2018

Fingerprint

Nausea
Vomiting
Drug Therapy
Neoplasms
Gastrointestinal Neoplasms
Antiemetics
Poisons
Patient Education
Informed Consent
Health Personnel
Research Personnel
Clinical Trials
Interviews
Muscles
Therapeutics

Keywords

  • Antiemetics
  • Nausea and vomiting
  • Qualitative
  • Supportive care
  • Underreporting

ASJC Scopus subject areas

  • Oncology

Cite this

@article{ae189b2f151b4f3bb2e6f37e0680b05b,
title = "What occurs in the other 20{\%} of cancer patients with chemotherapy-induced nausea and vomiting (CINV)? A single-institution qualitative study",
abstract = "Purpose: Despite recent advances in prophylaxis and management, 20{\%} of patients who receive moderately to severely emetogenic chemotherapy continue to experience nausea and vomiting. Relying on patients’ own words, this study sought to capture and characterize the lived experience with chemotherapy-induced nausea and vomiting (CINV) for this important subgroup of patients. Methods: Solid tumor patients with a history of poorly controlled CINV provided informed consent and participated in a semi-structured interview, which was audio-recorded and transcribed. After data saturation, enrollment ceased, and inductive, qualitative analytic methods were employed. Results: The median age of the 20 enrolled patients was 56 years (range 27–83) with an equal gender split; half had gastrointestinal cancers. Two themes emerged. First, CINV is severe and multidimensional: “It’s like shredding your muscles… It’s doing it over and over again.” This symptom complex has psychosocial implications: “Isolation is a big thing.” Financial toxicity is also implicated: “I use [an antiemetic] when I feel like it is absolutely necessary because it is so expensive I cannot afford it anyway.” The second theme is underreporting of symptoms. Patients seemed to accept N/V as part of treatment and were therefore less forthcoming: “God, if you’re pumping poison in your system, you gotta expect some side effects.” Conclusions: These vivid data should motivate investigators to continue conducting clinical trials CINV and should remind healthcare providers about the importance of patient education on the availability of therapy for breakthrough symptomatology.",
keywords = "Antiemetics, Nausea and vomiting, Qualitative, Supportive care, Underreporting",
author = "Childs, {Daniel S.} and Sherry Looker and Jennifer Le-Rademacher and Ridgeway, {Jennifer L.} and {Radecki Breitkopf}, Carmen and Aminah Jatoi",
year = "2018",
month = "6",
day = "25",
doi = "10.1007/s00520-018-4323-x",
language = "English (US)",
pages = "1--7",
journal = "Supportive Care in Cancer",
issn = "0941-4355",
publisher = "Springer Verlag",

}

TY - JOUR

T1 - What occurs in the other 20% of cancer patients with chemotherapy-induced nausea and vomiting (CINV)? A single-institution qualitative study

AU - Childs, Daniel S.

AU - Looker, Sherry

AU - Le-Rademacher, Jennifer

AU - Ridgeway, Jennifer L.

AU - Radecki Breitkopf, Carmen

AU - Jatoi, Aminah

PY - 2018/6/25

Y1 - 2018/6/25

N2 - Purpose: Despite recent advances in prophylaxis and management, 20% of patients who receive moderately to severely emetogenic chemotherapy continue to experience nausea and vomiting. Relying on patients’ own words, this study sought to capture and characterize the lived experience with chemotherapy-induced nausea and vomiting (CINV) for this important subgroup of patients. Methods: Solid tumor patients with a history of poorly controlled CINV provided informed consent and participated in a semi-structured interview, which was audio-recorded and transcribed. After data saturation, enrollment ceased, and inductive, qualitative analytic methods were employed. Results: The median age of the 20 enrolled patients was 56 years (range 27–83) with an equal gender split; half had gastrointestinal cancers. Two themes emerged. First, CINV is severe and multidimensional: “It’s like shredding your muscles… It’s doing it over and over again.” This symptom complex has psychosocial implications: “Isolation is a big thing.” Financial toxicity is also implicated: “I use [an antiemetic] when I feel like it is absolutely necessary because it is so expensive I cannot afford it anyway.” The second theme is underreporting of symptoms. Patients seemed to accept N/V as part of treatment and were therefore less forthcoming: “God, if you’re pumping poison in your system, you gotta expect some side effects.” Conclusions: These vivid data should motivate investigators to continue conducting clinical trials CINV and should remind healthcare providers about the importance of patient education on the availability of therapy for breakthrough symptomatology.

AB - Purpose: Despite recent advances in prophylaxis and management, 20% of patients who receive moderately to severely emetogenic chemotherapy continue to experience nausea and vomiting. Relying on patients’ own words, this study sought to capture and characterize the lived experience with chemotherapy-induced nausea and vomiting (CINV) for this important subgroup of patients. Methods: Solid tumor patients with a history of poorly controlled CINV provided informed consent and participated in a semi-structured interview, which was audio-recorded and transcribed. After data saturation, enrollment ceased, and inductive, qualitative analytic methods were employed. Results: The median age of the 20 enrolled patients was 56 years (range 27–83) with an equal gender split; half had gastrointestinal cancers. Two themes emerged. First, CINV is severe and multidimensional: “It’s like shredding your muscles… It’s doing it over and over again.” This symptom complex has psychosocial implications: “Isolation is a big thing.” Financial toxicity is also implicated: “I use [an antiemetic] when I feel like it is absolutely necessary because it is so expensive I cannot afford it anyway.” The second theme is underreporting of symptoms. Patients seemed to accept N/V as part of treatment and were therefore less forthcoming: “God, if you’re pumping poison in your system, you gotta expect some side effects.” Conclusions: These vivid data should motivate investigators to continue conducting clinical trials CINV and should remind healthcare providers about the importance of patient education on the availability of therapy for breakthrough symptomatology.

KW - Antiemetics

KW - Nausea and vomiting

KW - Qualitative

KW - Supportive care

KW - Underreporting

UR - http://www.scopus.com/inward/record.url?scp=85049005477&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85049005477&partnerID=8YFLogxK

U2 - 10.1007/s00520-018-4323-x

DO - 10.1007/s00520-018-4323-x

M3 - Article

SP - 1

EP - 7

JO - Supportive Care in Cancer

JF - Supportive Care in Cancer

SN - 0941-4355

ER -